Bolt Biotherapeutics (BOLT) Status Update summary

Financial and operational highlights

• Cash, cash equivalents, and marketable securities totaled $58 million as of March 31, expected to fund key milestones through mid-2026.

• Cost reduction initiatives include sale of lab equipment for $1 million and a second sublease to lower operating costs.

• Focus remains on efficient development and partnering to accelerate clinical programs.

BDC-3042 phase I clinical trial update

• BDC-3042, a first-in-class dectin-2 agonist antibody, showed a favorable safety profile with no grade 4/5 drug-related adverse events or dose-limiting toxicities up to 10 mg/kg every two weeks.

• Evidence of biological activity and immune stimulation observed, with promising antitumor activity, especially in non-small cell lung cancer (NSCLC) patients refractory to prior therapies.

• One NSCLC patient achieved a confirmed partial response, and others maintained stable disease, with ongoing treatment and good quality of life.

• Dectin-2 expression is high in tumor-associated macrophages across many cancers, supporting broad applicability.

BDC-4182 and pipeline progress

• Enrollment opened for the first-in-human phase I study of BDC-4182, a Claudin 18.2-targeting ISAC, in gastric and gastroesophageal cancer.

• Preclinical data show BDC-4182 outperforms ADCs in low Claudin 18.2-expressing tumors and induces immunological memory.

• The trial aims to expand the addressable market beyond high expressors, with early clinical data expected in early next year.

• Additional proprietary ISAC programs targeting CEA and PD-L1 are advancing, with strong interest from the scientific community.